CN102861051A - Application of Houttuynoid A in medicine for treating renal cancer - Google Patents
Application of Houttuynoid A in medicine for treating renal cancer Download PDFInfo
- Publication number
- CN102861051A CN102861051A CN2012104180790A CN201210418079A CN102861051A CN 102861051 A CN102861051 A CN 102861051A CN 2012104180790 A CN2012104180790 A CN 2012104180790A CN 201210418079 A CN201210418079 A CN 201210418079A CN 102861051 A CN102861051 A CN 102861051A
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- medicine
- renal cancer
- application
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses application of Houttuynoid A in preparing a medicine for treating renal cancer, which belongs to the technical field of new application of the medicine. According to the assessment on the antineoplastic activity through in-vitro MTT method, Houttuynoid A has an obvious inhibiting effect on the growth of human renal cancer cell strain KC. Therefore, Houttuynoid A can be used for preparing the medicine for preventing renal cancer, and has a favorable development and application prospect. The application of Houttuynoid A in preparing the medicine for treating renal cancer, which is provided by the invention, is disclosed for the first time, and because the skeleton type belongs to brand-new skeleton type, the inhibiting activity of Houttuynoid A to renal cancer cells is extremely strong.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid A, relate in particular to the application of Houttuynoid A in the anti-renal carcinoma medicine of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid A that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid A that the present invention relates in preparation treatment renal carcinoma medicine, because framework types belongs to brand-new framework types, and its inhibition for kidney cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously renal carcinoma obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid A in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid A in the anti-renal carcinoma medicine of preparation, and the structural formula of Houttuynoid A is shown in formula I:
The present invention finds that by external MTT anti-tumor activity evaluation Houttuynoid A also has significant inhibitory action to the growth of human renal carcinoma cell strain KC, suppresses the IC of this 1 strain Growth of Cells
50Value is respectively 3 ~ 4 μ M.Therefore, Houttuynoid A can for the preparation of anti-renal carcinoma medicine, have good development prospect.
The purposes of the Houttuynoid A that the present invention relates in preparation treatment renal carcinoma medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for kidney cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously renal carcinoma obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid A involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid A tablet involved in the present invention:
Get 20 and digest compound Houttuynoid A, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid A capsule involved in the present invention:
Get 20 and digest compound Houttuynoid A, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Houttuynoid A to the growth inhibited effect of human renal carcinoma cell strain
1. method: the cell that is in the growth logarithmic (log) phase: human renal carcinoma cell strain KC(buys from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, 0.01 μ M, 0.001 μ M, the culture medium of the Houttuynoid A of 0.0001 μ M and 0.00001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Houttuynoid A has significant inhibitory action to the growth of human renal carcinoma cell strain KC.This chemical compound suppresses the IC of human renal carcinoma cell strain KC growth
50Value is respectively: 3.56 ± 0.42 μ M.
Shown that by above-described embodiment Houttuynoid A of the present invention has good inhibitory action to the growth of human renal carcinoma cell strain KC.Prove that thus it is active that Houttuynoid A of the present invention has anti-renal carcinoma, can be for the preparation of anti-renal carcinoma medicine.
Claims (1)
1.Houttuynoid the application of A in treatment renal carcinoma medicine, described compound H outtuynoid A structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104180790A CN102861051A (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid A in medicine for treating renal cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104180790A CN102861051A (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid A in medicine for treating renal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102861051A true CN102861051A (en) | 2013-01-09 |
Family
ID=47440369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012104180790A Withdrawn CN102861051A (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid A in medicine for treating renal cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102861051A (en) |
-
2012
- 2012-10-27 CN CN2012104180790A patent/CN102861051A/en not_active Withdrawn
Non-Patent Citations (2)
| Title |
|---|
| 郭艳华等: "鱼腥草总黄酮的提取纯化及黄酮类型的初步鉴定 ", 《食品科学》 * |
| 郭艳华等: "鱼腥草总黄酮的提取纯化及黄酮类型的初步鉴定", 《食品科学》, vol. 28, no. 09, 31 December 2007 (2007-12-31), pages 1772 - 1775 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872135B (en) | Application of Houttuynoid D in drug for treating renal cancer | |
| CN102861052B (en) | Application of Houttuynoid A in medicine for treating ileocecum cancer | |
| CN102861056B (en) | Application of Houttuynoid A in endometrial cancer treatment medicine | |
| CN102872095B (en) | Application of Houttuynoid E in medicine for treating ileocecum cancer | |
| CN102872101B (en) | Application of Houttuynoid C in medicine for treating ileocecum cancer | |
| CN102861059B (en) | Application of Houttuynoid D in pancreatic cancer treatment medicine | |
| CN102872072B (en) | Application of Houttuynoid B to preparing drugs for treating kidney cancer | |
| CN102872149B (en) | Application of Houttuynoid B in medicament for treating cecum cancer | |
| CN102861062B (en) | Application of Houttuynoid C in endometrial cancer treatment medicine | |
| CN102872109B (en) | Application of Houttuynoid A in medicament for treating prostate cancer | |
| CN102872150B (en) | Application of Houttuynoid B in medicament for treating prostatic cancer | |
| CN102861084B (en) | Application of Houttuynoid D in medicine for treating ileocecum cancer | |
| CN102861070B (en) | Application of Houttuynoid E in medicine for treating tongue cancer | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102861050A (en) | Application of Houttuynoid A in medicine for treating pancreatic cancer | |
| CN102861099A (en) | Application of Houttuynoid D in medicine for treating endometrial cancer | |
| CN102861051A (en) | Application of Houttuynoid A in medicine for treating renal cancer | |
| CN102872092A (en) | Application of Houttuynoid E in medicine for treating kidney cancer | |
| CN102861048A (en) | Application of Houttuynoid A in medicine for treating nasopharyngeal carcinoma | |
| CN102861046A (en) | Application of Houttuynoid A in ovarian cancer treatment medicine | |
| CN102872074A (en) | Application of Houttuynoid C in drugs for treating kidney cancer | |
| CN102872103A (en) | Application of Houttuynoid E in medicine for treating nasopharyngeal carcinoma | |
| CN102861074A (en) | Application of Houttuynoid B in medicine for treating bladder cancer | |
| CN102872088A (en) | Application of Houttuynoid D in medicines for treating nasopharyngeal carcinoma | |
| CN102861080A (en) | Application of Houttuynoid C in medicine for treating nasopharynx cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20130109 |